Berman Capital Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Berman Capital Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$3K	Buy	133 +89	+202%	+$3.24K	﹤0.01%	1611
2021 Q2	$1K	Sell	44 -296	-87%	-$12.9K	﹤0.01%	1794
2021 Q1	$15K	Buy	340 +296	+673%	+$16.3K	﹤0.01%	902
2020 Q4	$2K	Hold	44	–	–	﹤0.01%	1429
2020 Q3	$1K	Hold	44	–	–	﹤0.01%	1500
2020 Q2	$0	Buy	+44	New	+$793	﹤0.01%	1779

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Berman Capital Advisors's RCKT Position: Q3 2021 in Review

Berman Capital Advisors increased its Rocket Pharmaceuticals (RCKT) stake by 202% in Q3 2021, buying an estimated $3.24K and bringing the position to 133 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Berman Capital Advisors first reported a position in RCKT in Q2 2020 and has held it in 6 quarters since. The position peaked at $15K in Q1 2021. 146 funds tracked by Wall St. Rank hold RCKT as of Q3 2021.

Berman Capital Advisors held 133 shares of Rocket Pharmaceuticals worth $3K as of Q3 2021.
Berman Capital Advisors bought 89 Rocket Pharmaceuticals shares in Q3 2021, an estimated $3.24K.
Rocket Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1611 holding.
Berman Capital Advisors first reported a position in Rocket Pharmaceuticals in Q2 2020 and has held it in 6 quarters since.
Berman Capital Advisors's Rocket Pharmaceuticals position peaked at $15K in Q1 2021.
146 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.